These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 22135725)

  • 21. Imatinib mesylate (STI571) interference with growth of neuroectodermal tumour cell lines does not critically involve c-Kit inhibition.
    Te Kronnie G; Timeus F; Rinaldi A; Crescenzio N; Spinelli M; Rosolen A; Ricotti E; Basso G
    Int J Mol Med; 2004 Sep; 14(3):373-82. PubMed ID: 15289888
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Response to imatinib mesylate of a gastrointestinal stromal tumor with very low expression of KIT.
    Bauer S; Corless CL; Heinrich MC; Dirsch O; Antoch G; Kanja J; Seeber S; Schütte J
    Cancer Chemother Pharmacol; 2003 Mar; 51(3):261-5. PubMed ID: 12655446
    [TBL] [Abstract][Full Text] [Related]  

  • 23. XB130 expression in human osteosarcoma: a clinical and experimental study.
    Wang X; Wang R; Liu Z; Hao F; Huang H; Guo W
    Int J Clin Exp Pathol; 2015; 8(3):2565-73. PubMed ID: 26045762
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The effect of imatinib mesylate on the proliferation, invasive ability, and radiosensitivity of retinoblastoma cell lines.
    de Moura LR; Marshall JC; Di Cesare S; Fernandes BF; Antecka E; Burnier MN
    Eye (Lond); 2013 Jan; 27(1):92-9. PubMed ID: 23154488
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Secondary mutation of c-kit/PDGFRα genotypes after imatinib mesylate therapy and its relationship with efficacy of sunitinib].
    Hong JL; Li J; Li J; Shen L
    Zhonghua Bing Li Xue Za Zhi; 2012 Jun; 41(6):386-90. PubMed ID: 22932406
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Synergistic antiproliferative effect of imatinib and adriamycin in platelet-derived growth factor receptor-expressing osteosarcoma cells.
    Yamaguchi SI; Ueki A; Sugihara E; Onishi N; Yaguchi T; Kawakami Y; Horiuchi K; Morioka H; Matsumoto M; Nakamura M; Muto A; Toyama Y; Saya H; Shimizu T
    Cancer Sci; 2015 Jul; 106(7):875-82. PubMed ID: 25940371
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Paradoxical and contradictory effects of imatinib in two cell line models of hormone-refractory prostate cancer.
    Cardoso HJ; Vaz CV; Correia S; Figueira MI; Marques R; Maia CJ; Socorro S
    Prostate; 2015 Jun; 75(9):923-35. PubMed ID: 25786656
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lack of c-kit (CD117) expression in CD30+ lymphomas and lymphomatoid papulosis.
    Rassidakis GZ; Georgakis GV; Oyarzo M; Younes A; Medeiros LJ
    Mod Pathol; 2004 Aug; 17(8):946-53. PubMed ID: 15105813
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical and molecular studies of the effect of imatinib on advanced aggressive fibromatosis (desmoid tumor).
    Heinrich MC; McArthur GA; Demetri GD; Joensuu H; Bono P; Herrmann R; Hirte H; Cresta S; Koslin DB; Corless CL; Dirnhofer S; van Oosterom AT; Nikolova Z; Dimitrijevic S; Fletcher JA
    J Clin Oncol; 2006 Mar; 24(7):1195-203. PubMed ID: 16505440
    [TBL] [Abstract][Full Text] [Related]  

  • 30. C-KIT overexpression and mutation in nasopharyngeal carcinoma cell lines and reactivity of Imatinib on these cell lines.
    Huang PY; Hong MH; Zhang X; Mai HQ; Luo DH; Zhang L
    Chin J Cancer; 2010 Feb; 29(2):131-5. PubMed ID: 20109338
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Expression of Kit and platelet-derived growth factor receptors alpha and beta in cholangiocarcinoma, and case report of therapy with imatinib mesylate (STI571).
    Holcombe RF; Gu M; Imagawa D; Milovanovic T
    Anticancer Drugs; 2003 Sep; 14(8):651-7. PubMed ID: 14501388
    [TBL] [Abstract][Full Text] [Related]  

  • 32. c-Kit is preferentially expressed in MYCN-amplified neuroblastoma and its effect on cell proliferation is inhibited in vitro by STI-571.
    Vitali R; Cesi V; Nicotra MR; McDowell HP; Donfrancesco A; Mannarino O; Natali PG; Raschellà G; Dominici C
    Int J Cancer; 2003 Aug; 106(2):147-52. PubMed ID: 12800187
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Imatinib mesylate inhibits platelet-derived growth factor receptor phosphorylation of melanoma cells but does not affect tumorigenicity in vivo.
    McGary EC; Onn A; Mills L; Heimberger A; Eton O; Thomas GW; Shtivelband M; Bar-Eli M
    J Invest Dermatol; 2004 Feb; 122(2):400-5. PubMed ID: 15009722
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of blocking platelet-derived growth factor-receptor signaling in a mouse model of experimental prostate cancer bone metastases.
    Uehara H; Kim SJ; Karashima T; Shepherd DL; Fan D; Tsan R; Killion JJ; Logothetis C; Mathew P; Fidler IJ
    J Natl Cancer Inst; 2003 Mar; 95(6):458-70. PubMed ID: 12644539
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Imatinib mesylate (gleevec)--targeted kinases are expressed in uterine sarcomas.
    Caudell JJ; Deavers MT; Slomovitz BM; Lu KH; Broaddus RR; Gershenson DM; Ramondetta LM
    Appl Immunohistochem Mol Morphol; 2005 Jun; 13(2):167-70. PubMed ID: 15894930
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunohistochemical expression of receptor-tyrosine kinase c-kit protein in invasive ductal carcinoma of the pancreas.
    Nio Y; Omori H; Toga T; Hashimoto K; Itakura M; Koike M; Yano S; Higami T
    Anticancer Drugs; 2003 Apr; 14(4):313-9. PubMed ID: 12679736
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Re: Potential use of imatinib in Ewing's sarcoma: evidence for in vitro and in vivo activity.
    Tamborini E; Bonadiman L; Albertini V; Pierotti MA; Pilotti S
    J Natl Cancer Inst; 2003 Jul; 95(14):1087-8; author reply 1088-9. PubMed ID: 12865456
    [No Abstract]   [Full Text] [Related]  

  • 38. Imatinib mesylate treatment of recurrent meningiomas in preselected patients: a retrospective analysis.
    Horak P; Wöhrer A; Hassler M; Hainfellner J; Preusser M; Marosi C
    J Neurooncol; 2012 Sep; 109(2):323-30. PubMed ID: 22610940
    [TBL] [Abstract][Full Text] [Related]  

  • 39. c-Kit mediates chemoresistance and tumor-initiating capacity of ovarian cancer cells through activation of Wnt/β-catenin-ATP-binding cassette G2 signaling.
    Chau WK; Ip CK; Mak AS; Lai HC; Wong AS
    Oncogene; 2013 May; 32(22):2767-81. PubMed ID: 22797058
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Management of malignant gastrointestinal stromal tumours.
    Joensuu H; Fletcher C; Dimitrijevic S; Silberman S; Roberts P; Demetri G
    Lancet Oncol; 2002 Nov; 3(11):655-64. PubMed ID: 12424067
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.